Rationale and design of a double-blinded, randomized placebo-controlled trial of 40 Hz light neurostimulation therapy for depression (FELIX)

• Published in: Annals of medicine (Helsinki) Vol. 56; no. 1; p. 2354852
• Main Authors: Sakalauskaitė, Laura, Hansen, Luna S, Dubois, Julie Margrethe, Ploug Larsen, Malina, Feijóo, Gustavo Miguel, Carstensen, Marcus S, Woznica Miskowiak, Kamilla, Nguyen, Mai, Harder Clemmensen, Line Katrine, Petersen, Paul Michael, Martiny, Klaus
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 11.05.2024; Taylor & Francis Group
• Subjects: 40 Hz stimulation; Adolescent; Adult; Aged; cognition; Depressive Disorder, Major - therapy; Double-Blind Method; Electroencephalography - methods; Female; gamma brainwaves; Gamma Rhythm - physiology; Humans; Light stimulation; major depressive disorder; Male; Method; Middle Aged; Phototherapy - methods; Psychiatry; Treatment Outcome; visual flicker; Young Adult; Light stimulation; visual flicker; cognition; gamma brainwaves; major depressive disorder; 40 Hz stimulation
• ISSN: 0785-3890; 1365-2060; 1365-2060
• DOI: 10.1080/07853890.2024.2354852

Major depressive disorder (MDD) is a debilitating condition that affects more than 300 million people worldwide. Current treatments are based on a trial-and-error approach, and reliable biomarkers are needed for more informed and personalized treatment solutions. One of the potential biomarkers, gamma-frequency (30-80 Hz) brainwaves, are hypothesized to originate from the excitatory-inhibitory interaction between the pyramidal cells and interneurons. The imbalance between this interaction is described as a crucial pathological mechanism in neuropsychiatric conditions, including MDD, and the modulation of this pathological interaction has been investigated as a potential target. Previous studies attempted to induce gamma activity in the brain using rhythmic light and sound stimuli (GENUS - Gamma Entrainment Using Sensory stimuli) that resulted in neuroprotective effects in Alzheimer's disease (AD) patients and animal models. Here, we investigate the antidepressant, cognitive, and electrophysiological effects of the novel light therapy approach using 40 Hz masked flickering light for patients diagnosed with MDD. Sixty patients with a current diagnosis of a major depressive episode will be enrolled in a randomized, double-blinded, placebo-controlled trial. The active treatment group will receive 40 Hz masked flickering light stimulation while the control group will receive continuous light matched in color temperature and brightness. Patients in both groups will get daily light treatment in their own homes and will attend four follow-up visits to assess the symptoms of depression, including depression severity measured by Hamilton Depression Rating Scale (HAM-D ), cognitive function, quality of life and sleep, and electroencephalographic changes. The primary endpoint is the mean change from baseline to week 6 in depression severity (HAM-D subscale) between the groups.